Thalia Therapeutics advances clinical-stage RNA strategy with Sanmirna acquisition and £2.75 million fundraising (THAT)
Thalia Therapeutics (LSE:THAT) is strengthening its position in the RNA therapeutics sector through the proposed acquisition of Sanmirna Therapeutics and ...